BioNexus Gene Lab Corp. Accounts Receivable, Allowance for Credit Loss, Recovery
BioNexus Gene Lab Corp. (BGLC) reported Accounts Receivable, Allowance for Credit Loss, Recovery of $91.38 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › and Others › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries · last filed 2026-08-14
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, recovery for the quarter ending 2026-06-30 was $91.38K, a 31.00% increase year-over-year.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, recovery for the quarter ending 2026-03-31 was $26.74K, a 6.32% increase year-over-year.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, recovery for the quarter ending 2025-12-31 was $2.29K.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, recovery for the quarter ending 2025-09-30 was $0.00.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, recovery for fiscal 2024 was $1.69M.
- BioNexus Gene Lab Corp. accounts receivable, allowance for credit loss, recovery for fiscal 2023 was $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss, Recovery 3 month | Accounts Receivable, Allowance for Credit Loss, Recovery 6 month | Accounts Receivable, Allowance for Credit Loss, Recovery 9 month | Accounts Receivable, Allowance for Credit Loss, Recovery 12 month |
|---|---|---|---|---|
| 2026-06-30 | $91.38K 10-Q · filed 2026-08-14 | $118.13K 10-Q · filed 2026-08-14 | $120.42K derived: sum of 3 quarters · filed 2026-08-14 | $120.42K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $26.74K 10-Q · filed 2026-05-15 | $29.03K derived: sum of 2 quarters · filed 2026-05-15 | $29.03K derived: sum of 3 quarters · filed 2026-05-15 | $98.79K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.29K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-05-15 | $2.29K derived: sum of 2 quarters · filed 2026-05-15 | $72.05K derived: sum of 3 quarters · filed 2026-08-14 | $97.20K 10-Q · filed 2026-05-15 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $69.76K derived: sum of 2 quarters · filed 2026-08-14 | $94.91K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $69.76K 10-Q · filed 2026-08-14 | $94.91K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $25.15K 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $1.69M 10-K · filed 2026-04-14 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |